M
Michele Caraglia
Researcher at Seconda Università degli Studi di Napoli
Publications - 562
Citations - 24508
Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.
Papers
More filters
Journal ArticleDOI
Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O2ˉ· production in cancer cells
Marco Cordani,Marco Cordani,Giovanna Butera,Ilaria Dando,Margalida Torrens-Mas,Elena Butturini,Raffaella Pacchiana,Elisa Oppici,Chiara Cavallini,Sara Gasperini,Nicola Tamassia,Mercedes Nadal-Serrano,Michela Coan,Davide Rossi,Gianluca Gaidano,Michele Caraglia,Sofia Mariotto,Riccardo Spizzo,Pilar Roca,Jordi Oliver,Maria Teresa Scupoli,Massimo Donadelli +21 more
TL;DR: The restoration of the mitochondrial uncoupling protein 2 (UCP2) expression, as well as the addition of the radical scavenger N-acetyl-l-cysteine, reversed the oncogenic effects of mutant p53 as cellular hyper-proliferation, antiapoptotic effect, and resistance to drugs.
Journal ArticleDOI
Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.
Paolo Grieco,Renato Franco,Giuseppina Bozzuto,Laura Toccacieli,Alessandro Sgambato,Monica Marra,Silvia Zappavigna,Mario Migaldi,Giulio Rossi,S. Striano,Luigi Marra,Luigi Gallo,Achille Cittadini,Gerardo Botti,Ettore Novellino,Agnese Molinari,Alfredo Budillon,Michele Caraglia +17 more
TL;DR: Data suggest that UTR can be considered a prognostic marker in human prostate adenocarcinoma patients, and the effects of an antagonist of UTR, urantide on migration and invasion of LNCaP cells.
Journal ArticleDOI
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience.
Pietro Paolo Vitiello,Vincenzo De Falco,Emilio Francesco Giunta,Davide Ciardiello,Claudia Cardone,P. Vitale,N. Zanaletti,C. Borrelli,L. Poliero,M. Terminiello,G. Arrichiello,V. Caputo,Vincenzo Famiglietti,Valentina Mattera Iacono,Francesca Marrone,Alessandra Di Liello,Giulia Martini,Stefania Napolitano,Michele Caraglia,Angela Lombardi,Renato Franco,Ferdinando De Vita,Floriana Morgillo,Teresa Troiani,Fortunato Ciardiello,Erika Martinelli +25 more
TL;DR: Testing RAS/BRAF mutations on plasma using the Idylla™ Biocartis platform is feasible and reliable in mCRC patients in clinical practice and correlated the results of liquid biopsy and standard tissue-based next generation sequencing analyses to patient clinical features.
Journal ArticleDOI
Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients.
Monica Lamberti,Rosanna Capasso,Angela Lombardi,Marina Di Domenico,Alfonso Fiorelli,Antonia Feola,Alessandra F. Perna,Mario Santini,Michele Caraglia,Diego Ingrosso +9 more
TL;DR: It is suggested that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
Journal ArticleDOI
Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells.
Monica Marra,Daniele Santini,Giuseppina Meo,Bruno Vincenzi,Silvia Zappavigna,Alfonso Baldi,Maciej Rosolowski,Giuseppe Tonini,Markus Loeffler,Ruth Lupu,Santolo Rosario Addeo,Alberto Abbruzzese,Alfredo Budillon,Michele Caraglia +13 more
TL;DR: It is found that CYR 61 protein expression was decreased significantly after exposure to ZOL, and the role of CYR61 in the regulation of growth inhibition and invasion/motility of PC3 cells is investigated using a shRNA for CyR61 to downregulate the expression of CYr61 protein.